| Name | Title | Contact Details |
|---|
InfraScan, Inc. is a medical device company that focuses on developing, commercializing, and distributing hand-held diagnostic devices for head injury and stroke assessment based on near infrared (NIR) technology. The Infrascanner enables clinicians to detect effectively, conveniently, and accurately intracranial bleeding in patients with head trauma. Intracranial hematomas are an important treatable cause of secondary brain injury in patients with head trauma. Recent statistics from Iraq shows that 30% of all wounded in action have head injuries; of them 40% have brain hematomas. Dr. Britton Chance (University of Pennsylvania) and Dr. Claudia Robertson (Baylor College of Medicine) invented a NIR system for detection of brain Hematomas and tested it successfully in 305 patients in Baylor. An entrepreneurial team formed a company around this technology in Collaboration with Drexel University and won the Wharton Business Plan competition in April 2004 and the second prize at the global business plan competition in Singapore in October 2004. Office of Naval Research funded the company in May 2004. The company also attracted $1.5M in funding from BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, from Ben Franklin Technology Partners of Southeastern Pennsylvania, and from Philadelphia Industrial Development Corporation. A multicenter clinical study to support an FDA submission started in July 2006, and on February 2008 an application was submitted to the FDA. After 4 years of review, the FDA cleared Infrascanner Model 1000 as a DeNovo medical technology in December 2011. In January 2013 the FDA cleared the 510(k) of Infrascanner Model 2000.
Del Mar Medical is a Mount Juliet, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Davidson is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Planmeca is the only manufacturer in the industry who can offer integrated equipment and software solution for specific needs of dental education and large university clinics. Our software and the digital platform of the dental units enable remote
Volpara Health Technologies Limited is a leading provider of breast imaging analytics and analysis products that improve clinical decision-making and the early detection of breast cancer. Every day, Volpara software helps clinicians better understand their patients and administrators better understand their practices. Volpara Health Technologies Limited (formerly Matakina Technology Limited) is a research, development, and manufacturing company based in Wellington, New Zealand. With a diverse research team led by internationally recognized experts in medical physics, as well as proprietary medical imaging technology covered by multiple patents and trademarks, we apply science to the solving of clinical problems around the world. Volpara Health Technologies Limited holds certification to ISO13485 and is a US FDA–registered establishment whose products are listed accordingly. In addition, our products hold CE Marking under European Medical Device Directive 93/42/EEC. Volpara Solutions Limited is our wholly owned sales and marketing subsidiary.